Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments
I want to filter the trials based on location, phase of development, or drug name, category or target
Prexasertib
No preference
No preference

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT02203513IIRecurrent high grade serous or endometrioid or germline BRCA1/2-mutated ovarian cancerA Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian CancerMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Prexasertibcheckpoint kinase 1 inhibitor LY2606368, LY2606368Chk1/2 inhibitorClinical Trials
NCT03057145IHigh grade serous, BRCA1/2-mutated ovarian cancer with progression on prior PARP inhibitorPhase 1 Combination Study of Prexasertib (LY2606368), CHK1 Inhibitor, and Olaparib, PARP Inhibitor, in Patients With Advanced Solid TumorsMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Prexasertibcheckpoint kinase 1 inhibitor LY2606368, LY2606368Chk1/2 inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03495323IAdvanced solid tumors (in expansion)A Phase I Combination Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid TumorsMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Prexasertibcheckpoint kinase 1 inhibitor LY2606368, LY2606368Chk1/2 inhibitorClinical Trials
LodapolimabLY3300054Blocks PD-L1 inhibition of T cellsClinical Trials

If you have any questions or would like help with your search, please call us at: 858-264-5124 or email us at patientsupport@clearityfoundation.org.